Sign In
Get Clay Free →

Suggestions

    Christopher A. Klebanoff, M.D.

    Associate Member, Memorial Sloan Kettering Cancer Center

    Christopher A. Klebanoff, M.D., is a prominent cellular immunologist and medical oncologist currently serving as a Scientific Co-founder and Advisor at Affini-T Therapeutics. His expertise focuses on T cell receptor (TCR) development and targeting oncogenic mutations, particularly in the context of solid tumors.

    Professional Background

    • Current Role: At Affini-T Therapeutics, Dr. Klebanoff collaborates closely with the company to advance innovative therapies aimed at treating solid tumors through precision immunotherapy. He joined Affini-T in April 2023 following a licensing agreement with Memorial Sloan Kettering Cancer Center (MSK), where he continues to lead his research lab.12

    • Affiliations: Dr. Klebanoff is also an Associate Member and Attending Physician at MSK, where he heads the Human Oncology and Pathogenesis Program and is a member of the Center for Cell Engineering.34 His work emphasizes the intersection of clinical practice and research, focusing on addressing urgent patient needs in cancer treatment.

    • Research Focus: His laboratory specializes in T cell immunobiology and adoptive T cell immunotherapy, contributing significantly to the understanding of tumor biology and T cell dynamics within solid tumors.67

    Contributions to Cancer Research

    Dr. Klebanoff's contributions have been recognized within the scientific community for their potential to transform cancer therapies. His work aims to overcome challenges in treating solid tumors by enhancing T cell fitness and targeting specific oncogenes.15 He has expressed a commitment to advancing groundbreaking research that translates into effective clinical therapies for patients.2

    Related Questions

    What are Dr. Klebanoff's key contributions to KRAS targeting?
    How does Dr. Klebanoff's work at MSK complement his role at Affini-T Therapeutics?
    What are the main goals of the collaboration between Affini-T Therapeutics and Memorial Sloan Kettering Cancer Center?
    Can you provide more details on the licensing agreement between Affini-T Therapeutics and MSK?
    What specific therapies is Dr. Klebanoff developing for solid tumors?
    Christopher A. Klebanoff, M.D.
    Christopher A. Klebanoff, M.D., photo 1
    Christopher A. Klebanoff, M.D., photo 2
    Get intro to Christopher
    Add to my network

    Experience

    Associate Member and Attending Physician at Memorial Sloan Kettering Cancer Center
    Scientific co-founder at Affini-T Therapeutics, Investigator and Parker Institute Faculty Fellow at Parker Institute for Cancer Immunotherapy, Assistant Member at Memorial Sloan Kettering Cancer Center (Sep 2016 - Mar 2023), Assistant Clinical Investigator at National Cancer Institute (Jun 2013 - Aug 2016), Senior Clinical and Research Fellow at National Cancer Institute (Jul 2012 - Jun 2013), Medical Oncology Clinical and Research Fellow at National Cancer Institute (Jul 2008 - Jun 2012), Resident of Internal Medicine at Johns Hopkins Hospital (Jul 2006 - Jun 2008), HHMI-NIH Research Scholar at Howard Hughes Medical Institute (Jun 2002 - Jun 2004)

    Education

    M.D. from Emory University School of Medicine (2000 - 2006), B.S. in Chemistry from Emory University (1996 - 2000)

    Location

    New York, New York, United States